Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients
FA Tadesse, AA Leminie - Frontiers in Oncology, 2023 - frontiersin.org
Background Adriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast
cancer (BC) patients. Its electrolyte and hematological adverse effects have not been …
cancer (BC) patients. Its electrolyte and hematological adverse effects have not been …